Audentes Therapeutics (BOLD) Tops Q4 EPS by 58c

Audentes Therapeutics (NASDAQ: BOLD) reported Q4 EPS of ($0.58), $0.58 better than the analyst estimate of ($1.16).

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• Robinhood Ventures Fund II opens at $22.50, IPO at $25
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c